瑞典卡罗琳医学院的研究发现，患有房颤和阿尔茨海默病的患者使用新型口服抗凝血药（NOACs）相比使用华法林或不用抗凝血药，认知功能衰退速度明显较慢1。该研究对7,308名同时患有这两种疾病的患者数据进行了分析1，发现NOACs治疗组患者的年度认知功能下降幅度比对照组少超过0.2个简易认知状态检查量表（MMSE）分值1。
除认知益处外，NOACs组患者在其他临床预后方面也表现出优势1。使用这类新型抗凝血药的患者死亡、卒中、血栓和骨折的风险均低于未服用抗凝血药的患者1。相比之下，华法林使用者则面临较高的大出血风险1。这项研究的数据来自瑞典认知障碍和痴呆全国质量登记库（SveDem），已在2026年发表于《欧洲心脏杂志》1。
Researchers at Sweden's Karolinska Institute have identified an unexpected benefit of newer anticoagulant medications for patients suffering from both atrial fibrillation and Alzheimer's disease. A study analyzing data from 7,308 patients with both conditions found that those taking novel oral anticoagulants (NOACs) experienced significantly slower cognitive decline compared to patients using warfarin or no anticoagulant therapy.1 The annual rate of cognitive deterioration, as measured by the Mini-Mental State Examination (MMSE), was more than 0.2 points better in the NOAC group relative to comparison groups.1
Beyond the cognitive benefits, the research revealed additional advantages associated with NOAC use.1 Patients treated with NOACs demonstrated reduced risk of death, stroke, blood clots, and fractures compared to those not receiving anticoagulant therapy.1 The study also noted elevated rates of severe bleeding among patients taking warfarin.1 The findings, led by Professor Maria Eriksdotter from the Department of Neurobiology, Care Sciences and Society at the Karolinska Institute, were published in the European Heart Journal in 2026.1 The research drew on data from SveDem, Sweden's national quality registry for cognitive disorders and dementia.1
评论
还没有评论，欢迎留下第一条。